Cargando…

Perioperative outcomes of zero ischemia radiofrequency ablation-assisted tumor enucleation for renal cell carcinoma: results of 182 patients

BACKGROUND: To evaluate the perioperative outcomes of zero ischemia radiofrequency ablation-assisted tumor enucleation. METHODS: Patients undergoing zero ischemia radiofrequency ablation-assisted tumor enucleation were retrospectively identified from July 2008 to March 2013. The tumor was enucleated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chengwei, Zhao, Xiaozhi, Guo, Suhan, Ji, Changwei, Wang, Wei, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952571/
https://www.ncbi.nlm.nih.gov/pubmed/29764415
http://dx.doi.org/10.1186/s12894-018-0356-1
Descripción
Sumario:BACKGROUND: To evaluate the perioperative outcomes of zero ischemia radiofrequency ablation-assisted tumor enucleation. METHODS: Patients undergoing zero ischemia radiofrequency ablation-assisted tumor enucleation were retrospectively identified from July 2008 to March 2013. The tumor was enucleated after RFA treatment. R.E.N.A.L., PADUA and centrality index (C-index) score systems were used to assess each tumor case. We analyzed the correlation of perioperative outcomes with these scores. Postoperative complications were graded with Clavien-Dindo system. Multivariate logistic regression analyses were used to assess risk of complications. RESULTS: Among 182 patients assessed, median tumor size, estimated blood loss, hospital stay and operative time were 3.2 cm (IQR 2.8–3.4), 80 ml (IQR 50–120), 7 days (IQR 6–8) and 100 min (IQR 90–120), respectively. All three scoring systems were strongly correlated with estimated blood loss, hospital stay and operative time. We found 3 (1.6%) intraoperative and 23 (12.6%, 13 [7.1%] Grade 1 and 10 [5.5%] Grade 2 & 3a) postoperative complications. The median follow-up was 55.5 months (IQR 45–70). Additionally, the complexities of R.E.N.A.L., PADUA and C-index scores were significantly correlated with complication grades (P < 0.001; P < 0.001; P < 0.001; respectively). As the representative, R.E.N.A.L. score was an independent predictive factor for postoperative complications and patients with a high complexity had an over 24-fold higher risk compared to those with a low complexity (OR 24.360, 95% CI 4.412–134.493, P < 0.001). CONCLUSIONS: Zero ischemia radiofrequency ablation-assisted tumor enucleation is considered an effective nephron-sparing treatment. Scoring systems could be useful for predicting perioperative outcomes of radiofrequency ablation-assisted tumor enucleation.